Compare CTW & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTW | KALA |
|---|---|---|
| Founded | 2013 | 2009 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.6M | 172.0M |
| IPO Year | N/A | 2017 |
| Metric | CTW | KALA |
|---|---|---|
| Price | $2.47 | $2.25 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $31.50 |
| AVG Volume (30 Days) | 28.9K | ★ 1.2M |
| Earning Date | 05-13-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 67.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.41 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.10 | $0.07 |
| 52 Week High | $3.14 | $20.58 |
| Indicator | CTW | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 47.27 | 59.31 |
| Support Level | $1.88 | $0.32 |
| Resistance Level | $2.68 | $3.96 |
| Average True Range (ATR) | 0.23 | 0.37 |
| MACD | -0.07 | -0.07 |
| Stochastic Oscillator | 37.97 | 7.27 |
CTW Cayman operates the web-based HTML5 gaming platform G123.jp, offering free-to-play games based on Japanese animations, including Queen's Blade, So I'm a Spider, So What?, and Goblin Slayer. The platform features 29 games, with 11 in pre-registration. The Group provides a platform for game developers to generate revenue and reach an international audience through shared revenue from players' in-game purchases. It operates in Japan, Singapore, Taiwan, and China, excluding Taiwan, with the majority of revenue derived from Japan, and has one reporting segment focused on game distribution and related services.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.